Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Leukemia, Myeloid, Acute 69Breast Neoplasms 51Carcinoma, Non-Small-Cell Lung 28Neoplasms 27Myelodysplastic Syndromes 27Advanced Solid Tumors 27Advanced Solid Tumor 26Prostatic Neoplasms 23Stomach Neoplasms 19Recurrence 18Multiple Myeloma 18Neoplasm Metastasis 17Carcinoma, Hepatocellular 17Ovarian Neoplasms 15Lung Neoplasms 15Pancreatic Neoplasms 14Uterine Cervical Neoplasms 13Solid Tumor 13Sarcoma 13Melanoma 13Leukemia, Myelomonocytic, Chronic 13Colorectal Neoplasms 11Triple Negative Breast Neoplasms 10Small Cell Lung Carcinoma 10Lymphoma, Large B-Cell, Diffuse 10Squamous Cell Carcinoma of Head and Neck 8Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Esophageal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

Irinotecan 8Bevacizumab 8Fluorouracil 7Leucovorin 6Oxaliplatin 5Capecitabine 45,10-methylenetetrahydrofolic acid 3Radiotherapy 2Levoleucovorin 2Folfox protocol 2Drug Therapy 2Cetuximab 2Bisacodyl 2Aspirin 2Artesunate 2trametinib 1spartalizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1nazartinib 1napabucasin 1guadecitabine 1encorafenib 1canakinumab 1camrelizumab 1apatinib 1alectinib 1aldesleukin 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Intestinal Neoplasms × Injections × Clear all
NCT06078670 2023-10-12

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Fujian Cancer Hospital

Phase 1/2 Not yet recruiting
96 enrolled
BreastGastrointestinal

Intestinal Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡